Literature DB >> 22751536

The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance.

Aurelia M Schmalstieg1, Shashikant Srivastava, Serkan Belkaya, Devyani Deshpande, Claudia Meek, Richard Leff, Nicolai S C van Oers, Tawanda Gumbo.   

Abstract

We hypothesize that low-level efflux pump expression is the first step in the development of high-level drug resistance in mycobacteria. We performed 28-day azithromycin dose-effect and dose-scheduling studies in our hollow-fiber model of disseminated Mycobacterium avium-M. intracellulare complex. Both microbial kill and resistance emergence were most closely linked to the within-macrophage area under the concentration-time curve (AUC)/MIC ratio. Quantitative PCR revealed that subtherapeutic azithromycin exposures over 3 days led to a 56-fold increase in expression of MAV_3306, which encodes a putative ABC transporter, and MAV_1406, which encodes a putative major facilitator superfamily pump, in M. avium. By day 7, a subpopulation of M. avium with low-level resistance was encountered and exhibited the classic inverted U curve versus AUC/MIC ratios. The resistance was abolished by an efflux pump inhibitor. While the maximal microbial kill started to decrease after day 7, a population with high-level azithromycin resistance appeared at day 28. This resistance could not be reversed by efflux pump inhibitors. Orthologs of pumps encoded by MAV_3306 and MAV_1406 were identified in Mycobacterium tuberculosis, Mycobacterium leprae, Mycobacterium marinum, Mycobacterium abscessus, and Mycobacterium ulcerans. All had highly conserved protein secondary structures. We propose that induction of several efflux pumps is the first step in a general pathway to drug resistance that eventually leads to high-level chromosomal-mutation-related resistance in mycobacteria as ordered events in an "antibiotic resistance arrow of time."

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22751536      PMCID: PMC3421847          DOI: 10.1128/AAC.05546-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  45 in total

1.  Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux.

Authors:  Gail E Louw; Robin M Warren; Nicolaas C Gey van Pittius; Rosalba Leon; Adelina Jimenez; Rogelio Hernandez-Pando; Christopher R E McEvoy; Melanie Grobbelaar; Megan Murray; Paul D van Helden; Thomas C Victor
Journal:  Am J Respir Crit Care Med       Date:  2011-04-21       Impact factor: 21.405

2.  Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.

Authors:  Jotam G Pasipanodya; Shashikant Srivastava; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2012-03-30       Impact factor: 9.079

3.  Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB.

Authors:  Seok-Yong Eum; Ji-Hye Kong; Min-Sun Hong; Ye-Jin Lee; Jin-Hee Kim; Soo-Hee Hwang; Sang-Nae Cho; Laura E Via; Clifton E Barry
Journal:  Chest       Date:  2009-09-11       Impact factor: 9.410

4.  Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.

Authors:  Devyani Deshpande; Shashikant Srivastava; Claudia Meek; Richard Leff; Gerri S Hall; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

5.  Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol.

Authors:  Shashikant Srivastava; Sandirai Musuka; Carleton Sherman; Claudia Meek; Richard Leff; Tawanda Gumbo
Journal:  J Infect Dis       Date:  2010-04-15       Impact factor: 5.226

6.  Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.

Authors:  Tianyu Zhang; William R Bishai; Jacques H Grosset; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2010-04-26       Impact factor: 5.191

Review 7.  A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs.

Authors:  Jotam G Pasipanodya; Tawanda Gumbo
Journal:  Curr Opin Pharmacol       Date:  2011-07-30       Impact factor: 5.547

8.  Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium.

Authors:  Devyani Deshpande; Shashikant Srivastava; Claudia Meek; Richard Leff; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

9.  Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability.

Authors:  Shashikant Srivastava; Jotam G Pasipanodya; Claudia Meek; Richard Leff; Tawanda Gumbo
Journal:  J Infect Dis       Date:  2011-10-21       Impact factor: 5.226

Review 10.  Pharmacokinetic/pharmacodynamic-based treatment of disseminated Mycobacterium avium.

Authors:  Devyani Deshpande; Tawanda Gumbo
Journal:  Future Microbiol       Date:  2011-04       Impact factor: 3.165

View more
  66 in total

1.  Biological variability and the emergence of multidrug-resistant tuberculosis.

Authors:  Tawanda Gumbo
Journal:  Nat Genet       Date:  2013-07       Impact factor: 38.330

2.  Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease.

Authors:  Shashikant Srivastava; Jotam Pasipanodya; Carleton M Sherman; Claudia Meek; Richard Leff; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

3.  Clofazimine for the Treatment of Mycobacterium kansasii.

Authors:  Shashikant Srivastava; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

4.  Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.

Authors:  Xubin Zheng; Rongrong Zheng; Yi Hu; Jim Werngren; Lina Davies Forsman; Mikael Mansjö; Biao Xu; Sven Hoffner
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

5.  Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy.

Authors:  Tawanda Gumbo; Jotam G Pasipanodya; Peter Wash; André Burger; Helen McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

6.  Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-Resistant Mycobacterium massiliense Lung Disease.

Authors:  Hayoung Choi; Su-Young Kim; Hyun Lee; Byung Woo Jhun; Hye Yun Park; Kyeongman Jeon; Dae Hun Kim; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Seung-Heon Lee; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

7.  Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease.

Authors:  Seong Mi Moon; Hye Yun Park; Su-Young Kim; Byung Woo Jhun; Hyun Lee; Kyeongman Jeon; Dae Hun Kim; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Hong Kwan Kim; Yong Soo Choi; Jhingook Kim; Seung-Heon Lee; Chang Ki Kim; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

8.  An upstream truncation of the furA-katG operon confers high-level isoniazid resistance in a Mycobacterium tuberculosis clinical isolate with no known resistance-associated mutations.

Authors:  Gilman Kit Hang Siu; Wing Cheong Yam; Ying Zhang; Richard Y T Kao
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

9.  Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection.

Authors:  Beatriz E Ferro; Shashikant Srivastava; Devyani Deshpande; Jotam G Pasipanodya; Dick van Soolingen; Johan W Mouton; Jakko van Ingen; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

Review 10.  Novel adjunctive therapies for the treatment of tuberculosis.

Authors:  A A Ordonez; M Maiga; S Gupta; E A Weinstein; W R Bishai; S K Jain
Journal:  Curr Mol Med       Date:  2014-03       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.